Research Triangle Park, NC, May 20, 2019 — T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959 (the “Company”), a new orally administered treatment for Alzheimer’s disease (AD), announced today that it has received a grant...
T3D Therapeutics, Inc. today announced that final Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in a session at the 2018 Alzheimer’s Association International Conference (AAIC) entitled ‘Novel Therapeutic Approaches for...
T3D Therapeutics, Inc. today announced that FDG-PET neuroimaging data from a Phase 2a trial with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in an oral and poster presentation entitled ‘A Neurometabolic Approach to Treating Alzheimer’s...
RESEARCH TRIANGLE PARK, NC (PRWEB) MARCH 28, 2017 – T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen Welsh-Bohmer...
Research Triangle Park, NC (PRWEB) November 30, 2016 — T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that CEO, John Didsbury, will...
T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that preliminary Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease...
